All News
Kimme Hydrich: There is no increased of "exceedingly rare" vaccination adverse effects in rheumatic patients
💉APLS is NOT a risk factor for thrombotic AEs with vaccination
#EULAR2022 @Rheumnow @rheum_covid
Eric Dein ericdeinmd ( View Tweet)
HAS-GCA study @alwinuk @profbdasgupta Southend pretest probability score and Halo score useful in diagnosis and prognosis in GCA. Halo score may be useful for monitoring. @RheumNow #EULAR2022 POS0818 https://t.co/sxYjnQQFA8
Richard Conway RichardPAConway ( View Tweet)
Do you vaccine pts w/ RMDs for shingles?
If so, when and who and with what?
@khyrich highlights differences in recommendations and contra-indications across countries
#EULAR2022 @RheumNow https://t.co/c0uvOPopF4
Aurelie Najm AurelieRheumo ( View Tweet)
“One of the benefits of #vaccinations people don’t talk about is the relief they feel after vaccination."
- Dr E Hyrich #EULAR2022 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
RheumNow’s coverage of the #EULAR2022 Annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
💫Trajectory analysis in SpA💫
Data on 1,125 patients
Prediction of spinal radiographic progression
⭐️FAST associated w/ onset at older age & 👁involvement
⭐️SLOW progression associated w/ female gender & peripheral involvement.
#EULAR2022 @RheumNow OP0151 https://t.co/E80qCLEtBv
Aurelie Najm AurelieRheumo ( View Tweet)
Preito-Pena at al. Tocilizumab in LVV-GCA and TAK. Similar responses in both, with 75% showing complete clinical response but only 20% complete imaging response at month 12. Clinical implications of these persistent imaging findings need clarification @RheumNow #EULAR2022 POS0804 https://t.co/sNbRzIkwnt
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022
"The mRNA vaccines are simple to make." - Saul Faust
The key step is encapsulation in lipid to allow for take up by cell.
💉💉💉
@RheumNow https://t.co/T2ZxF6bLV5
Eric Dein ericdeinmd ( View Tweet)
Comorbidity in AS from @rheum_cat , Karmacharya et al. Clustering of comorbidities. Depression and hypertension clusters assoc worse disease activity and function @RheumNow #EULAR2022 OP0154 https://t.co/jGQXayAYs9 https://t.co/SnVDhVYQq5
Links:
Richard Conway RichardPAConway ( View Tweet)
Flatman et al. Serious infections in babies born to women using TNFi during pregnancy. 2902 babies. Adjusted HR 1.20 (0.54-2.64) for agents with high vs low placental transfer. @RheumNow #EULAR2022 OP0130 https://t.co/oaW7wDPxva
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0134: Active RA increases risk of dementia
Olmsted County, MINN studying RA risk factors for dementia:
⭐️886 pts incident RA, mean age 65. 103 develop dementia
Risk factors: Age, rheum nodules, large jt swelling, depression/anxiety, HTN, CVD events
@Rheumnow https://t.co/bUFkzBovAy
Eric Dein ericdeinmd ( View Tweet)
Fonzetti et al. Isolated Ro-52 in pSS. 300 patients. Less inflammatory features but more fibrotic disease - ILD and PBC. @RheumNow #EULAR2022 OP0146 https://t.co/2WIAu8qKiH https://t.co/mspSBNxbx2
Links:
Richard Conway RichardPAConway ( View Tweet)
Prof T Dorner summarizes what's new in #SLE #EULAR2022
@rheumnow https://t.co/YT0Ocw7I41
TheDaoIndex KDAO2011 ( View Tweet)
Large collaborative study on IIM treatment patterns from @Nellziade @ElenaNikiUK @LatikaGupta_ @drhectorchinoy @MarcinMilchert and many others. Significant geographic differences, highlighting need for consensus guidelines @RheumNow #EULAR2022 OP0161 https://t.co/osaORtgvxh https://t.co/96PypMtlcl
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 OP0138:
BIOBADASER registry:
Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy
⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy
27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx
@Rheumnow https://t.co/nTuUooBmzV
Eric Dein ericdeinmd ( View Tweet)
Ghalandari et al EUDRAVIGILANCE database congenital malformations for non-TNFi bDMARDs (vs certolizumab). ORs suggest possible B-cell modulators and vedolizumab, not others. Geneticist rvw no pattern for B-cell agents. @RheumNow #EULAR2022 OP0129 https://t.co/nrj8MxjAri https://t.co/p6JkfjjtdH
Links:
Richard Conway RichardPAConway ( View Tweet)
Interestingly, anti-IFN Ab can be present in #SLE pts and impact the IFN signature.
There is a bimodal type I IFN signature in #SLE.
IFN and Blys signatures overlap (?distinct populations/interactions between the two?) - Prof T Dorner #EULAR2022 @rheumnow https://t.co/phLXv2KVxR
TheDaoIndex KDAO2011 ( View Tweet)
All the domains of sexual sphere are deteriorated in RA and PsA.
This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI
Aurelie Najm AurelieRheumo ( View Tweet)
Dr Puja Khanna. Transdermal sodium bicarbonate for gout flare. WHAT!? It works as well! Double-blind RCT. All got colchicine also. Response rate 95% vs 79%. Resolution in 24 vs 72 hrs. Rescue meds 6% vs 20%. No adverse events! @RheumNow #EULAR2022 OP0170 https://t.co/INd4tMFVlV https://t.co/EyVjFLF72z
Links:
Richard Conway RichardPAConway ( View Tweet)
#EULAR2022 ASAS/EULAR AxSpA Recs
⭐️Last: 2016
▶️All: education, exercise, 🚭
▶️❌csDMARD for axial disease
▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1
▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17
▶️Sustained remission: tapering of bDMARD "can be considered"
@RheumNow https://t.co/3yYU0Vb37r
Eric Dein ericdeinmd ( View Tweet)